<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en" dir="ltr">
  <head>
    <meta http-equiv="Content-Type" content="text/html; charset=UTF-8" />
    		<meta name="keywords" content="Antiarrhythmic agent,Antiarrhythmic agents,Major Drug Groups,Antiarrhythmic agents,Major Drug Groups,ACE inhibitor,ATC code C01,ATC code C07,ATC code C08,AV node,Acebutolol" />
		<link rel="shortcut icon" href="/favicon.ico" />
		<link rel="search" type="application/opensearchdescription+xml" href="/w/opensearch_desc.php" title="Wikipedia (English)" />
		<link rel="copyright" href="../../../COPYING.html" />
    <title>Antiarrhythmic agent - Wikipedia, the free encyclopedia</title>
    <style type="text/css">/*<![CDATA[*/ @import "../../../skins/htmldump/main.css"; /*]]>*/</style>
    <link rel="stylesheet" type="text/css" media="print" href="../../../skins/common/commonPrint.css" />
    <!--[if lt IE 5.5000]><style type="text/css">@import "../../../skins/monobook/IE50Fixes.css";</style><![endif]-->
    <!--[if IE 5.5000]><style type="text/css">@import "../../../skins/monobook/IE55Fixes.css";</style><![endif]-->
    <!--[if IE 6]><style type="text/css">@import "../../../skins/monobook/IE60Fixes.css";</style><![endif]-->
    <!--[if IE]><script type="text/javascript" src="../../../skins/common/IEFixes.js"></script>
    <meta http-equiv="imagetoolbar" content="no" /><![endif]-->
    <script type="text/javascript" src="../../../skins/common/wikibits.js"></script>
    <script type="text/javascript" src="../../../skins/htmldump/md5.js"></script>
    <script type="text/javascript" src="../../../skins/htmldump/utf8.js"></script>
    <script type="text/javascript" src="../../../skins/htmldump/lookup.js"></script>
    <script type="text/javascript" src="../../../raw/gen.js"></script>        <style type="text/css">/*<![CDATA[*/
@import "../../../raw/MediaWiki%7ECommon.css";
@import "../../../raw/MediaWiki%7EMonobook.css";
@import "../../../raw/gen.css";
/*]]>*/</style>          </head>
  <body
    class="ns-0">
    <div id="globalWrapper">
      <div id="column-content">
	<div id="content">
	  <a name="top" id="contentTop"></a>
	        <h1 class="firstHeading">Antiarrhythmic agent</h1>
	  <div id="bodyContent">
	    <h3 id="siteSub">From Wikipedia, the free encyclopedia</h3>
	    <div id="contentSub"></div>
	    	    <div class="usermessage">You have <a href="../../../1/2/7/User_talk%7E127.0.0.1.html" title="User talk:127.0.0.1">new messages</a> (<a href="../../../1/2/7/User_talk%7E127.0.0.1.html" title="User talk:127.0.0.1">last change</a>).</div>	    <!-- start content -->
	    <p><b>Antiarrhythmic agents</b> are a group of <a href="../../../p/h/a/Pharmaceutical.html" title="Pharmaceutical">pharmaceuticals</a> that are used to suppress fast rhythms of the <a href="../../../h/e/a/Heart.html" title="Heart">heart</a> (<a href="../../../c/a/r/Cardiac_arrhythmias.html" title="Cardiac arrhythmias">cardiac arrhythmias</a>), such as <a href="../../../a/t/r/Atrial_fibrillation.html" title="Atrial fibrillation">atrial fibrillation</a>, <a href="../../../a/t/r/Atrial_flutter.html" title="Atrial flutter">atrial flutter</a>, <a href="../../../v/e/n/Ventricular_tachycardia.html" title="Ventricular tachycardia">ventricular tachycardia</a>, and <a href="../../../v/e/n/Ventricular_fibrillation.html" title="Ventricular fibrillation">ventricular fibrillation</a>.</p>
<p>While the use of antiarrhythmic agents to suppress atrial arrhythmias (atrial fibrillation and atrial flutter) is still in practice, it is unclear whether suppression of atrial arrhythmias will prolong life.<sup id="_ref-0" class="reference"><a href="#_note-0" title="">[1]</a></sup><sup id="_ref-1" class="reference"><a href="#_note-1" title="">[2]</a></sup></p>
<p>In the past, it was believed that following <a href="../../../m/y/o/Myocardial_infarction.html" title="Myocardial infarction">myocardial infarction</a> (heart attack), suppression of ventricular arrhythmias would prolong life. However large clinical trials found that suppression of these arrhythmias would paradoxically increase mortality,<sup id="_ref-2" class="reference"><a href="#_note-2" title="">[3]</a></sup><sup id="_ref-3" class="reference"><a href="#_note-3" title="">[4]</a></sup> which may happen due to the increased workload these drugs place on the heart.</p>
<p>In individuals with atrial fibrillation, antiarrhythmics are still used to suppress arrhythmias. This is often done to relieve the symptoms that may be associated with the loss of the atrial component to ventricular filling (<i>atrial kick</i>) that is due to <a href="../../../a/t/r/Atrial_fibrillation.html" title="Atrial fibrillation">atrial fibrillation</a> or <a href="../../../a/t/r/Atrial_flutter.html" title="Atrial flutter">flutter</a>.</p>
<p>In individuals with ventricular arrhythmias, antiarrhythmic agents are often still in use to suppress arrhythmias. In this case, the patient may have frequent arrhythmic events or be at high risk for ventricular arrhythmias. Antiarrhythmic agents may be considered the first-line therapy in the prevention of <a href="../../../c/a/r/Cardiac_arrest.html" title="Cardiac arrest">sudden death</a> in certain forms of structural heart disease, and failure of these agents to suppress arrhythmias may lead to implantation of an <a href="../../../i/m/p/Implantable_cardioverter-defibrillator.html" title="Implantable cardioverter-defibrillator">implantable cardioverter-defibrillator</a> (ICD).</p>
<p>The use of antiarrhythmic agents in this population may be in conjunction with an ICD. In this case, the ICD is used to prevent <a href="../../../c/a/r/Cardiac_arrest.html" title="Cardiac arrest">sudden death</a> due to ventricular fibrillation, while the antiarrhythmic agent(s) are used to suppress ventricular tachyarrhythmias so that the ICD doesn't shock the patient frequently.</p>
<div class="thumb tright">
<div class="thumbinner" style="width:277px;"><a href="../../../a/c/t/Image%7EAction_potential.png_7b4b.html" class="internal" title="The cardiac action potential"><img src="../../../upload/thumb/f/fd/Action_potential.png/275px-Action_potential.png" alt="The cardiac action potential" width="275" height="174" longdesc="../../../a/c/t/Image%7EAction_potential.png_7b4b.html" class="thumbimage" /></a>
<div class="thumbcaption">
<div class="magnify" style="float:right"><a href="../../../a/c/t/Image%7EAction_potential.png_7b4b.html" class="internal" title="Enlarge"><img src="../../../skins/common/images/magnify-clip.png" width="15" height="11" alt="" /></a></div>
The cardiac action potential</div>
</div>
</div>
<p>Many attempts have been made to classify antiarrhythmic agents. The problem arises from the fact that many of the antiarrhythmic agents have multiple modes of action, making any classification imprecise.</p>
<table id="toc" class="toc" summary="Contents">
<tr>
<td>
<div id="toctitle">
<h2>Contents</h2>
</div>
<ul>
<li class="toclevel-1"><a href="#Vaughan_Williams_antiarrhythmic_classification"><span class="tocnumber">1</span> <span class="toctext">Vaughan Williams antiarrhythmic classification</span></a>
<ul>
<li class="toclevel-2"><a href="#Class_I_agents"><span class="tocnumber">1.1</span> <span class="toctext">Class I agents</span></a>
<ul>
<li class="toclevel-3"><a href="#Class_Ia_agents"><span class="tocnumber">1.1.1</span> <span class="toctext">Class Ia agents</span></a></li>
<li class="toclevel-3"><a href="#Class_Ib_agents"><span class="tocnumber">1.1.2</span> <span class="toctext">Class Ib agents</span></a></li>
<li class="toclevel-3"><a href="#Class_Ic_agents"><span class="tocnumber">1.1.3</span> <span class="toctext">Class Ic agents</span></a></li>
</ul>
</li>
<li class="toclevel-2"><a href="#Class_II_agents"><span class="tocnumber">1.2</span> <span class="toctext">Class II agents</span></a></li>
<li class="toclevel-2"><a href="#Class_III_agents"><span class="tocnumber">1.3</span> <span class="toctext">Class III agents</span></a></li>
<li class="toclevel-2"><a href="#Class_IV_agents"><span class="tocnumber">1.4</span> <span class="toctext">Class IV agents</span></a></li>
<li class="toclevel-2"><a href="#Class_V_agents"><span class="tocnumber">1.5</span> <span class="toctext">Class V agents</span></a></li>
</ul>
</li>
<li class="toclevel-1"><a href="#See_also"><span class="tocnumber">2</span> <span class="toctext">See also</span></a></li>
<li class="toclevel-1"><a href="#References"><span class="tocnumber">3</span> <span class="toctext">References</span></a></li>
</ul>
</td>
</tr>
</table>
<p><script type="text/javascript">
//<![CDATA[
 if (window.showTocToggle) { var tocShowText = "show"; var tocHideText = "hide"; showTocToggle(); } 
//]]>
</script><a name="Vaughan_Williams_antiarrhythmic_classification" id="Vaughan_Williams_antiarrhythmic_classification"></a></p>
<h2><span class="editsection">[<a href="../../../a/n/t/Antiarrhythmic_agent.html" title="Edit section: Vaughan Williams antiarrhythmic classification">edit</a>]</span> <span class="mw-headline">Vaughan Williams antiarrhythmic classification</span></h2>
<p>The Vaughan Williams classification is one of the most widely used classification schemes for antiarrhythmic agents. This scheme classifies a drug based on the primary mechanism of its antiarrhythmic effect. However, its dependence on primary mechanism is one of the limitations of the VW classification, since many antiarrhythmic agents have multiple action mechanisms. <a href="../../../a/m/i/Amiodarone.html" title="Amiodarone">Amiodarone</a>, for example, has effects consistent with all of the first four classes. Another limitation is the lack of consideration within the VW classification system for the effects of drug metabolites. <a href="../../../p/r/o/Procainamide.html" title="Procainamide">Procainamide</a>—a class Ia agent whose metabolite <a href="../../../n/-/a/N-acetyl_procainamide.html" title="N-acetyl procainamide">N-acetyl procainamide</a> (NAPA) has a class III action—is one such example. A historical limitation was that drugs such as <a href="../../../d/i/g/Digoxin.html" title="Digoxin">digoxin</a> and <a href="../../../a/d/e/Adenosine.html" title="Adenosine">adenosine</a> – important antiarrhythmic agents – had no place at all in the VW classification system. This has since been rectified by the inclusion of class V.</p>
<p>There are five main classes in the Vaughan Williams classification of antiarrhythmic agents:</p>
<ul>
<li>Class I agents interfere with the <a href="../../../s/o/d/Sodium.html" title="Sodium">sodium</a> (Na<sup>+</sup>) channel.</li>
<li>Class II agents are anti-<a href="../../../s/y/m/Sympathetic_nervous_system.html" title="Sympathetic nervous system">sympathetic nervous system</a> agents. All agents in this class are <a href="../../../b/e/t/Beta_blockers.html" title="Beta blockers">beta blockers</a>.</li>
<li>Class III agents affect <a href="../../../p/o/t/Potassium.html" title="Potassium">potassium</a> (K<sup>+</sup>) efflux.</li>
<li>Class IV agents affect the <a href="../../../a/v/_/AV_node_985a.html" title="AV node">AV node</a>.</li>
<li>Class V agents work by other or unknown mechanisms.</li>
</ul>
<p><a name="Class_I_agents" id="Class_I_agents"></a></p>
<h3><span class="editsection">[<a href="../../../a/n/t/Antiarrhythmic_agent.html" title="Edit section: Class I agents">edit</a>]</span> <span class="mw-headline">Class I agents</span></h3>
<p>The class I antiarrhythmic agents interfere with the <a href="../../../s/o/d/Sodium.html" title="Sodium">sodium</a> (Na<sup>+</sup>) channel. Class I agents are grouped by what effect they have on the Na<sup>+</sup> channel, and what effect they have on cardiac <a href="../../../a/c/t/Action_potential.html" title="Action potential">action potentials</a>.</p>
<p><a name="Class_Ia_agents" id="Class_Ia_agents"></a></p>
<h4><span class="editsection">[<a href="../../../a/n/t/Antiarrhythmic_agent.html" title="Edit section: Class Ia agents">edit</a>]</span> <span class="mw-headline">Class Ia agents</span></h4>
<div class="thumb tright">
<div class="thumbinner" style="width:277px;"><a href="../../../a/c/t/Image%7EAction_potential_Class_Ia.png_b628.html" class="internal" title="Class Ia agent decreasing Vmax, thereby increasing action potential duration."><img src="../../../upload/thumb/c/c9/Action_potential_Class_Ia.png/275px-Action_potential_Class_Ia.png" alt="Class Ia agent decreasing Vmax, thereby increasing action potential duration." width="275" height="151" longdesc="../../../a/c/t/Image%7EAction_potential_Class_Ia.png_b628.html" class="thumbimage" /></a>
<div class="thumbcaption">
<div class="magnify" style="float:right"><a href="../../../a/c/t/Image%7EAction_potential_Class_Ia.png_b628.html" class="internal" title="Enlarge"><img src="../../../skins/common/images/magnify-clip.png" width="15" height="11" alt="" /></a></div>
Class Ia agent decreasing V<sub>max</sub>, thereby increasing action potential duration.</div>
</div>
</div>
<p>Class Ia agents block the fast sodium channel. Blocking this channel depresses the phase 0 depolarization (reduces V<sub>max</sub>), which prolongs the action potential duration by slowing conduction. Agents in this class also cause decreased conductivity and increased refractoriness.</p>
<p>Indications for Class Ia agents are <a href="../../../s/u/p/Supraventricular_tachycardia.html" title="Supraventricular tachycardia">supraventricular tachycardia</a>, <a href="../../../v/e/n/Ventricular_tachycardia.html" title="Ventricular tachycardia">ventricular tachycardia</a>, symptomatic ventricular premature beats, and prevention of <a href="../../../v/e/n/Ventricular_fibrillation.html" title="Ventricular fibrillation">ventricular fibrillation</a>.</p>
<p>Procainamide can be used in the treatment of <a href="../../../a/t/r/Atrial_fibrillation.html" title="Atrial fibrillation">atrial fibrillation</a> in the setting of <a href="../../../w/o/l/Wolff-Parkinson-White_syndrome_7bb0.html" title="Wolff-Parkinson-White syndrome">Wolff-Parkinson-White syndrome</a>, and in the treatment of wide complex hemodynamically stable <a href="../../../t/a/c/Tachycardia.html" title="Tachycardia">tachycardias</a>.</p>
<p>While procainamide and quinidine may be used in the conversion of atrial fibrillation to normal sinus rhythm, they should only be used in conjunction with an <a href="../../../a/v/_/AV_node_985a.html" title="AV node">AV node</a> blocking agent (ie: <a href="../../../d/i/g/Digoxin.html" title="Digoxin">digoxin</a>, <a href="../../../v/e/r/Verapamil.html" title="Verapamil">verapamil</a>, or a <a href="../../../b/e/t/Beta_blocker.html" title="Beta blocker">beta blocker</a>), because procainamide and quinidine can increase the conduction through the AV node and may cause 1:1 conduction of atrial fibrillation, causing an increase in the ventricular rate.</p>
<p>Class Ia agents include <a href="../../../q/u/i/Quinidine.html" title="Quinidine">quinidine</a>, <a href="../../../p/r/o/Procainamide.html" title="Procainamide">procainamide</a> and <a href="../../../d/i/s/Disopyramide.html" title="Disopyramide">disopyramide</a>.</p>
<p><a name="Class_Ib_agents" id="Class_Ib_agents"></a></p>
<h4><span class="editsection">[<a href="../../../a/n/t/Antiarrhythmic_agent.html" title="Edit section: Class Ib agents">edit</a>]</span> <span class="mw-headline">Class Ib agents</span></h4>
<div class="thumb tright">
<div class="thumbinner" style="width:277px;"><a href="../../../a/c/t/Image%7EAction_potential_Class_Ib.png_f010.html" class="internal" title="Effect of class Ib antiarrhythmic agents on the cardiac action potential."><img src="../../../upload/thumb/8/89/Action_potential_Class_Ib.png/275px-Action_potential_Class_Ib.png" alt="Effect of class Ib antiarrhythmic agents on the cardiac action potential." width="275" height="169" longdesc="../../../a/c/t/Image%7EAction_potential_Class_Ib.png_f010.html" class="thumbimage" /></a>
<div class="thumbcaption">
<div class="magnify" style="float:right"><a href="../../../a/c/t/Image%7EAction_potential_Class_Ib.png_f010.html" class="internal" title="Enlarge"><img src="../../../skins/common/images/magnify-clip.png" width="15" height="11" alt="" /></a></div>
Effect of class Ib antiarrhythmic agents on the cardiac action potential.</div>
</div>
</div>
<p>Class Ib antiarrhythmic agents are sodium channel blockers. Class Ib agents have fast onset and offset kinetics, meaning that they have little or no effect at slower heart rates, and more effects at faster heart rates. Class Ib agents shorten the action potential duration and reduce refractoriness. These agents will decrease V<sub>max</sub> in partially depolarized cells with fast response action potentials. They either do not change the action potential duration, or they may decrease the action potential duration.</p>
<p>Class Ib agents are indicated for the treatment of ventricular tachycardia and symptomatic premature ventricular beats, and prevention of ventricular fibrillation.</p>
<p>Class Ib agents include <a href="../../../l/i/d/Lidocaine.html" title="Lidocaine">lidocaine</a>, <a href="../../../m/e/x/Mexiletine.html" title="Mexiletine">mexiletine</a>, <a href="../../../t/o/c/Tocainide.html" title="Tocainide">tocainide</a>, and <a href="../../../p/h/e/Phenytoin.html" title="Phenytoin">phenytoin</a>.</p>
<p><a name="Class_Ic_agents" id="Class_Ic_agents"></a></p>
<h4><span class="editsection">[<a href="../../../a/n/t/Antiarrhythmic_agent.html" title="Edit section: Class Ic agents">edit</a>]</span> <span class="mw-headline">Class Ic agents</span></h4>
<div class="thumb tright">
<div class="thumbinner" style="width:277px;"><a href="../../../a/c/t/Image%7EAction_potential_Class_Ic.png_403a.html" class="internal" title="Effect of class Ic antiarrhythmic agent on cardiac action potential."><img src="../../../upload/thumb/f/f4/Action_potential_Class_Ic.png/275px-Action_potential_Class_Ic.png" alt="Effect of class Ic antiarrhythmic agent on cardiac action potential." width="275" height="163" longdesc="../../../a/c/t/Image%7EAction_potential_Class_Ic.png_403a.html" class="thumbimage" /></a>
<div class="thumbcaption">
<div class="magnify" style="float:right"><a href="../../../a/c/t/Image%7EAction_potential_Class_Ic.png_403a.html" class="internal" title="Enlarge"><img src="../../../skins/common/images/magnify-clip.png" width="15" height="11" alt="" /></a></div>
Effect of class Ic antiarrhythmic agent on cardiac action potential.</div>
</div>
</div>
<p>Class Ic antiarrhythmic agents markedly depress the phase 0 depolarization (decreasing V<sub>max</sub>). They decrease conductivity, but have a minimal effect on the action potential duration. Of the sodium channel blocking antiarrhythmic agents (the class I antiarrhythmic agents), the class Ic agents have the most potent sodium channel blocking effects.</p>
<p>Class Ic agents are indicated for life-threatening ventricular tachycardia or ventricular fibrillation, and for the treatment of refractory supraventricular tachycardia (ie: <a href="../../../a/t/r/Atrial_fibrillation.html" title="Atrial fibrillation">atrial fibrillation</a>).It can be toxic and can affect the reproductive system.</p>
<p>Class Ic agents include <a href="../../../e/n/c/Encainide.html" title="Encainide">encainide</a>, <a href="../../../f/l/e/Flecainide.html" title="Flecainide">flecainide</a>, <a href="../../../m/o/r/Moricizine.html" title="Moricizine">moricizine</a>, and <a href="../../../p/r/o/Propafenone.html" title="Propafenone">propafenone</a>.</p>
<p><a name="Class_II_agents" id="Class_II_agents"></a></p>
<h3><span class="editsection">[<a href="../../../a/n/t/Antiarrhythmic_agent.html" title="Edit section: Class II agents">edit</a>]</span> <span class="mw-headline">Class II agents</span></h3>
<p>Class II agents are conventional <a href="../../../b/e/t/Beta_blockers.html" title="Beta blockers">beta blockers</a>. They act by selectively blocking the effects of <a href="../../../c/a/t/Catecholamine.html" title="Catecholamine">catecholamines</a> at the <a href="../../../a/d/r/Adrenergic_receptor.html#Type_.CE.B21" title="Adrenergic receptor">β<sub>1</sub>-adrenergic receptors</a>, thereby decreasing sympathetic activity on the heart. These agents are particularly useful in the treatment of <a href="../../../s/u/p/Supraventricular_tachycardia.html" title="Supraventricular tachycardia">supraventricular tachycardias</a>. They decrease conduction through the <a href="../../../a/v/_/AV_node_985a.html" title="AV node">AV node</a>.</p>
<p>Class II agents include <a href="../../../e/s/m/Esmolol.html" title="Esmolol">esmolol</a>, <a href="../../../p/r/o/Propranolol.html" title="Propranolol">propranolol</a>, and <a href="../../../m/e/t/Metoprolol.html" title="Metoprolol">metoprolol</a>.</p>
<p><a name="Class_III_agents" id="Class_III_agents"></a></p>
<h3><span class="editsection">[<a href="../../../a/n/t/Antiarrhythmic_agent.html" title="Edit section: Class III agents">edit</a>]</span> <span class="mw-headline">Class III agents</span></h3>
<div class="thumb tright">
<div class="thumbinner" style="width:277px;"><a href="../../../a/c/t/Image%7EAction_potential_Class_III.png_6db2.html" class="internal" title="Effect of class III antiarrhythmic agent on cardiac action potential."><img src="../../../upload/thumb/0/0c/Action_potential_Class_III.png/275px-Action_potential_Class_III.png" alt="Effect of class III antiarrhythmic agent on cardiac action potential." width="275" height="148" longdesc="../../../a/c/t/Image%7EAction_potential_Class_III.png_6db2.html" class="thumbimage" /></a>
<div class="thumbcaption">
<div class="magnify" style="float:right"><a href="../../../a/c/t/Image%7EAction_potential_Class_III.png_6db2.html" class="internal" title="Enlarge"><img src="../../../skins/common/images/magnify-clip.png" width="15" height="11" alt="" /></a></div>
Effect of class III antiarrhythmic agent on cardiac action potential.</div>
</div>
</div>
<p>Class III agents predominantly block the potassium channels, thereby prolonging repolarization.<sup id="_ref-4" class="reference"><a href="#_note-4" title="">[5]</a></sup> Since these agents do not affect the sodium channel, conduction velocity is not decreased. The prolongation of the action potential duration and refractory period, combined with the maintenance of normal conduction velocity, prevent re-entrant arrhythmias. (The re-entrant rhythm is more like to interact with tissue that has become refractory).</p>
<p>Class III antiarrhythmic agents exhibit reverse use dependent prolongation of the action potential duration (<b>Reverse use-dependence</b>). This means that the refractoriness of the ventricular <a href="../../../m/y/o/Myocyte.html" title="Myocyte">myocyte</a> increases at lower <a href="../../../h/e/a/Heart_rate.html" title="Heart rate">heart rates</a>. This increases the susceptibility of the myocardium to early after-depolarizations (EADs) at low heart rates. Antiarrhythmic agents that exhibit reverse use-dependence are more efficacious at preventing a tachyarrhythmia than converting someone into normal sinus rhythm. <i>Because of the reverse use-dependence of class III agents, at low heart rates class III antiarrhythmic agents may paradoxically be more arrhythmogenic.</i></p>
<p>Amiodarone is indicated for the treatment of refractory <a href="../../../v/e/n/Ventricular_tachycardia.html" title="Ventricular tachycardia">VT</a> or <a href="../../../v/e/n/Ventricular_fibrillation.html" title="Ventricular fibrillation">VF</a>, particularly in the setting of acute ischemia. Amiodarone is also safe to use in individuals with <a href="../../../c/a/r/Cardiomyopathy.html" title="Cardiomyopathy">cardiomyopathy</a> and <a href="../../../a/t/r/Atrial_fibrillation.html" title="Atrial fibrillation">atrial fibrillation</a>, to maintain normal sinus rhythm.</p>
<p>Sotalol is indicated for the treatment of atrial or ventricular tachyarrhythmias, and AV re-entrant arrhythmias. Ibutilide is the only antiarrhythmic agent currently approved by the <a href="../../../f/o/o/Food_and_Drug_Administration_b75c.html" title="Food and Drug Administration">Food and Drug Administration</a> for acute conversion of <a href="../../../a/t/r/Atrial_fibrillation.html" title="Atrial fibrillation">atrial fibrillation</a> to sinus rhythm.</p>
<p>Class III agents include <a href="../../../a/m/i/Amiodarone.html" title="Amiodarone">amiodarone</a>, <a href="../../../a/z/i/Azimilide.html" title="Azimilide">azimilide</a>, <a href="../../../b/r/e/Bretylium.html" title="Bretylium">bretylium</a>, clofilium, <a href="../../../d/o/f/Dofetilide.html" title="Dofetilide">dofetilide</a>, tedisamil, <a href="../../../i/b/u/Ibutilide.html" title="Ibutilide">ibutilide</a>, sematilide, and <a href="../../../s/o/t/Sotalol.html" title="Sotalol">sotalol</a>.</p>
<p><a name="Class_IV_agents" id="Class_IV_agents"></a></p>
<h3><span class="editsection">[<a href="../../../a/n/t/Antiarrhythmic_agent.html" title="Edit section: Class IV agents">edit</a>]</span> <span class="mw-headline">Class IV agents</span></h3>
<p>Class IV agents are slow <a href="../../../c/a/l/Calcium_channel_blocker.html" title="Calcium channel blocker">calcium channel blockers</a>. They decrease conduction through the <a href="../../../a/v/_/AV_node_985a.html" title="AV node">AV node</a>.</p>
<p>Class IV agents include <a href="../../../v/e/r/Verapamil.html" title="Verapamil">verapamil</a> and <a href="../../../d/i/l/Diltiazem.html" title="Diltiazem">diltiazem</a>.</p>
<p><a name="Class_V_agents" id="Class_V_agents"></a></p>
<h3><span class="editsection">[<a href="../../../a/n/t/Antiarrhythmic_agent.html" title="Edit section: Class V agents">edit</a>]</span> <span class="mw-headline">Class V agents</span></h3>
<p>Class V agents include <a href="../../../d/i/g/Digoxin.html" title="Digoxin">digoxin</a> and <a href="../../../a/d/e/Adenosine.html" title="Adenosine">adenosine</a>. Digoxin increases vagal activity via its central action on the central nervous system, thus decreasing the conduction of electrical impulses through the AV node</p>
<p><a name="See_also" id="See_also"></a></p>
<h2><span class="editsection">[<a href="../../../a/n/t/Antiarrhythmic_agent.html" title="Edit section: See also">edit</a>]</span> <span class="mw-headline">See also</span></h2>
<ul>
<li><a href="../../../a/c/t/Action_potential.html" title="Action potential">Action potential</a>
<ul>
<li><a href="../../../c/a/r/Cardiac_action_potential.html" title="Cardiac action potential">Cardiac action potential</a></li>
</ul>
</li>
<li><a href="../../../e/l/e/Electrocardiogram.html" title="Electrocardiogram">Electrocardiogram</a></li>
</ul>
<p><a name="References" id="References"></a></p>
<h2><span class="editsection">[<a href="../../../a/n/t/Antiarrhythmic_agent.html" title="Edit section: References">edit</a>]</span> <span class="mw-headline">References</span></h2>
<ol class="references">
<li id="_note-0"><b><a href="#_ref-0" title="">^</a></b> <cite style="font-style:normal">Wyse D, Waldo A, DiMarco J, Domanski M, Rosenberg Y, Schron E, Kellen J, Greene H, Mickel M, Dalquist J, Corley S (2002). "A comparison of rate control and rhythm control in patients with atrial fibrillation.". <i>N Engl J Med</i> <b>347</b> (23): 1825-33. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12466506" class="external" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12466506">PMID 12466506</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.atitle=A+comparison+of+rate+control+and+rhythm+control+in+patients+with+atrial+fibrillation.&amp;rft.title=N+Engl+J+Med&amp;rft.jtitle=N+Engl+J+Med&amp;rft.date=2002&amp;rft.volume=347&amp;rft.issue=23&amp;rft.au=Wyse+D%2C+Waldo+A%2C+DiMarco+J%2C+Domanski+M%2C+Rosenberg+Y%2C+Schron+E%2C+Kellen+J%2C+Greene+H%2C+Mickel+M%2C+Dalquist+J%2C+Corley+S&amp;rft.pages=1825-33">&#160;</span></li>
<li id="_note-1"><b><a href="#_ref-1" title="">^</a></b> <cite style="font-style:normal">Nichol G, McAlister F, Pham B, Laupacis A, Shea B, Green M, Tang A, Wells G (2002). "Meta-analysis of randomised controlled trials of the effectiveness of antiarrhythmic agents at promoting sinus rhythm in patients with atrial fibrillation.". <i>Heart</i> <b>87</b> (6): 535-43. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12010934" class="external" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12010934">PMID 12010934</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.atitle=Meta-analysis+of+randomised+controlled+trials+of+the+effectiveness+of+antiarrhythmic+agents+at+promoting+sinus+rhythm+in+patients+with+atrial+fibrillation.&amp;rft.title=Heart&amp;rft.jtitle=Heart&amp;rft.date=2002&amp;rft.volume=87&amp;rft.issue=6&amp;rft.au=Nichol+G%2C+McAlister+F%2C+Pham+B%2C+Laupacis+A%2C+Shea+B%2C+Green+M%2C+Tang+A%2C+Wells+G&amp;rft.pages=535-43">&#160;</span></li>
<li id="_note-2"><b><a href="#_ref-2" title="">^</a></b> <cite style="font-style:normal">(1989) "Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. The Cardiac Arrhythmia Suppression Trial (CAST) Investigators.". <i>N Engl J Med</i> <b>321</b> (6): 406-12. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2473403" class="external" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2473403">PMID 2473403</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.atitle=Preliminary+report%3A+effect+of+encainide+and+flecainide+on+mortality+in+a+randomized+trial+of+arrhythmia+suppression+after+myocardial+infarction.+The+Cardiac+Arrhythmia+Suppression+Trial+%28CAST%29+Investigators.&amp;rft.title=N+Engl+J+Med&amp;rft.jtitle=N+Engl+J+Med&amp;rft.date=1989&amp;rft.volume=321&amp;rft.issue=6&amp;rft.pages=406-12">&#160;</span></li>
<li id="_note-3"><b><a href="#_ref-3" title="">^</a></b> <cite style="font-style:normal">(1992) "Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction. The Cardiac Arrhythmia Suppression Trial II Investigators.". <i>N Engl J Med</i> <b>327</b> (4): 227-33. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1377359" class="external" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1377359">PMID 1377359</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.atitle=Effect+of+the+antiarrhythmic+agent+moricizine+on+survival+after+myocardial+infarction.+The+Cardiac+Arrhythmia+Suppression+Trial+II+Investigators.&amp;rft.title=N+Engl+J+Med&amp;rft.jtitle=N+Engl+J+Med&amp;rft.date=1992&amp;rft.volume=327&amp;rft.issue=4&amp;rft.pages=227-33">&#160;</span></li>
<li id="_note-4"><b><a href="#_ref-4" title="">^</a></b> Lenz TL, Hilleman DE, Department of Cardiology, Creighton University, Omaha, Nebraska. Dofetilide, a New Class III Antiarrhythmic Agent. Pharmacotherapy 20(7):776-786, 2000. (<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10907968" class="external text" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10907968" rel="nofollow">Medline abstract</a>)</li>
</ol>
<table class="navbox collapsible" style="margin: auto;">
<tr>
<th colspan="2" style="text-align:center;">
<div class="noprint plainlinksneverexpand" style="background-color:transparent; padding:0; font-weight:normal; font-size:xx-small; color:#000000; white-space:nowrap; float:left;width:6em;text-align:left;"><a href="../../../a/n/t/Template%7EAntiarrhythmic_agents_1eb7.html" title="Template:Antiarrhythmic agents"><span title="View this template">v</span></a>&#160;<span style="font-size:80%;">•</span>&#160;<span style="color: #002bb8;" title="Discussion about this template">d</span>&#160;<span style="font-size:80%;">•</span>&#160;<a href="http://en.wikipedia.org../../../a/n/t/Template%7EAntiarrhythmic_agents_1eb7.html" class="external text" title="http://en.wikipedia.org../../../a/n/t/Template%7EAntiarrhythmic_agents_1eb7.html" rel="nofollow"><span style="color: #002bb8;" title="You can edit this template. Please use the preview button before saving.">e</span></a></div>
<strong class="selflink">Antiarrhythmic agents</strong> (<a href="../../../a/t/c/ATC_code_C01_98cd.html#C01B_Antiarrhythmics.2C_class_I_and_III" title="ATC code C01">C01B</a>)</th>
</tr>
<tr>
<th style="">class Ia</th>
<td><a href="../../../a/j/m/Ajmaline.html" title="Ajmaline">Ajmaline</a>, <a href="../../../d/i/s/Disopyramide.html" title="Disopyramide">Disopyramide</a>, <a href="../../../p/r/a/Prajmaline.html" title="Prajmaline">Prajmaline</a>, <a href="../../../p/r/o/Procainamide.html" title="Procainamide">Procainamide</a>, <a href="../../../q/u/i/Quinidine.html" title="Quinidine">Quinidine</a>, <a href="../../../s/p/a/Sparteine.html" title="Sparteine">Sparteine</a></td>
</tr>
<tr>
<th style="">class Ib</th>
<td><a href="../../../a/p/r/Aprindine.html" title="Aprindine">Aprindine</a>, <a href="../../../l/i/d/Lidocaine.html" title="Lidocaine">Lidocaine</a>, <a href="../../../m/e/x/Mexiletine.html" title="Mexiletine">Mexiletine</a>, <a href="../../../t/o/c/Tocainide.html" title="Tocainide">Tocainide</a></td>
</tr>
<tr>
<th style="">class Ic</th>
<td><a href="../../../e/n/c/Encainide.html" title="Encainide">Encainide</a>, <a href="../../../f/l/e/Flecainide.html" title="Flecainide">Flecainide</a>, <a href="../../../l/o/r/Lorcainide.html" title="Lorcainide">Lorcainide</a>, <a href="../../../m/o/r/Moricizine.html" title="Moricizine">Moricizine</a>, <a href="../../../p/r/o/Propafenone.html" title="Propafenone">Propafenone</a></td>
</tr>
<tr>
<th style="">class II</th>
<td><a href="../../../p/r/o/Propranolol.html" title="Propranolol">Propranolol</a>, <a href="../../../m/e/t/Metoprolol.html" title="Metoprolol">Metoprolol</a>, <a href="../../../n/a/d/Nadolol.html" title="Nadolol">Nadolol</a>, <a href="../../../a/t/e/Atenolol.html" title="Atenolol">Atenolol</a>, <a href="../../../a/c/e/Acebutolol.html" title="Acebutolol">Acebutolol</a>, <a href="../../../p/i/n/Pindolol.html" title="Pindolol">Pindolol</a><br />
<i>see <a href="../../../b/e/t/Beta_blockers.html" title="Beta blockers">Beta blockers</a> (<a href="../../../a/t/c/ATC_code_C07_0a08.html" title="ATC code C07">C07</a>)</i></td>
</tr>
<tr>
<th style="">class III</th>
<td><a href="../../../a/m/i/Amiodarone.html" title="Amiodarone">Amiodarone</a>, <a href="../../../b/r/e/Bretylium.html" title="Bretylium">Bretylium tosylate</a>, <a href="../../../b/u/n/Bunaftine.html" title="Bunaftine">Bunaftine</a>, <a href="../../../d/o/f/Dofetilide.html" title="Dofetilide">Dofetilide</a>, <a href="../../../i/b/u/Ibutilide.html" title="Ibutilide">Ibutilide</a>, <a href="../../../s/o/t/Sotalol.html" title="Sotalol">Sotalol</a></td>
</tr>
<tr>
<th style="">class IV</th>
<td><a href="../../../v/e/r/Verapamil.html" title="Verapamil">Verapamil</a>, <a href="../../../d/i/l/Diltiazem.html" title="Diltiazem">Diltiazem</a><br />
<i>see <a href="../../../c/a/l/Calcium_channel_blocker.html" title="Calcium channel blocker">Calcium channel blockers</a> (<a href="../../../a/t/c/ATC_code_C08_d3ef.html" title="ATC code C08">C08</a>)</i></td>
</tr>
<tr>
<th style="">class V</th>
<td><a href="../../../a/d/e/Adenosine.html" title="Adenosine">Adenosine</a>, <a href="../../../a/t/r/Atropine.html" title="Atropine">Atropine</a>, <a href="../../../d/i/g/Digoxin.html" title="Digoxin">Digoxin</a></td>
</tr>
</table>
<table class="navbox collapsible autocollapse" style="margin: auto; text-align:left">
<tr>
<th colspan="2" style="text-align:center;">
<div class="noprint plainlinksneverexpand" style="background-color:transparent; padding:0; font-weight:normal; font-size:xx-small; color:#000000; white-space:nowrap; float:left;width:6em;text-align:left;"><a href="../../../m/a/j/Template%7EMajor_Drug_Groups_2544.html" title="Template:Major Drug Groups"><span title="View this template">v</span></a>&#160;<span style="font-size:80%;">•</span>&#160;<a href="../../../m/a/j/Template_talk%7EMajor_Drug_Groups_149b.html" title="Template talk:Major Drug Groups"><span title="Discussion about this template">d</span></a>&#160;<span style="font-size:80%;">•</span>&#160;<a href="http://en.wikipedia.org../../../m/a/j/Template%7EMajor_Drug_Groups_2544.html" class="external text" title="http://en.wikipedia.org../../../m/a/j/Template%7EMajor_Drug_Groups_2544.html" rel="nofollow"><span style="color: #002bb8;" title="You can edit this template. Please use the preview button before saving.">e</span></a></div>
Major Drug Groups</th>
</tr>
<tr>
<th style=""><a href="../../../b/r/a/Brain.html" title="Brain">Brain</a> and <a href="../../../n/e/r/Nervous_system.html" title="Nervous system">Nervous system</a></th>
<td><a href="../../../a/n/a/Analgesic.html" title="Analgesic">Analgesics</a>, <a href="../../../a/n/e/Anesthesia.html" title="Anesthesia">Anesthetics</a>, <a href="../../../a/n/x/Anxiolytic.html" title="Anxiolytic">Anxiolytics</a>, <a href="../../../a/n/t/Antidepressant.html" title="Antidepressant">Antidepressants</a>, <a href="../../../a/n/t/Antipsychotic.html" title="Antipsychotic">Antipsychotics</a>, <a href="../../../a/n/t/Anticonvulsant.html" title="Anticonvulsant">Anticonvulsants</a>, <a href="../../../s/t/i/Stimulant.html" title="Stimulant">Nervous system stimulants</a>, <a href="../../../a/n/t/Antiemetic.html" title="Antiemetic">Antiemetics</a>, <a href="../../../p/s/y/Psychedelics%2C_dissociatives_and_deliriants.html" title="Psychedelics, dissociatives and deliriants">Hallucinogens</a>, <a href="../../../m/o/o/Mood_stabilizer.html" title="Mood stabilizer">Mood stabilizers</a></td>
</tr>
<tr>
<th style=""><a href="../../../r/e/s/Respiratory_system.html" title="Respiratory system">Respiratory system</a></th>
<td><a href="../../../b/r/o/Bronchodilator.html" title="Bronchodilator">Bronchodilators</a>, <a href="../../../d/e/c/Decongestant.html" title="Decongestant">Decongestants</a></td>
</tr>
<tr>
<th style=""><a href="../../../h/e/a/Heart.html" title="Heart">Heart</a> and <a href="../../../c/i/r/Circulatory_system.html" title="Circulatory system">Circulation</a></th>
<td><a href="../../../a/c/e/ACE_inhibitor_fd43.html" title="ACE inhibitor">Angiotensin converting enzyme inhibitors</a>, <strong class="selflink">Antiarrhythmics</strong>, <a href="../../../a/n/t/Antianginal.html" title="Antianginal">Antianginals</a>, <a href="../../../a/n/t/Antihypertensive.html" title="Antihypertensive">Antihypertensives</a>, <a href="../../../h/y/p/Hypolipidemic_agent.html" title="Hypolipidemic agent">Antihyperlipidemics</a>, <a href="../../../a/n/t/Anticoagulant.html" title="Anticoagulant">Anticoagulants</a>, <a href="../../../a/n/t/Antiplatelet_drug.html" title="Antiplatelet drug">Antiplatelets</a>, <a href="../../../b/e/t/Beta_blocker.html" title="Beta blocker">Beta blockers</a>, <a href="../../../d/i/u/Diuretic.html" title="Diuretic">Diuretics</a>, <a href="../../../t/h/r/Thrombolytic_drug.html" title="Thrombolytic drug">Thrombolytics</a>, <a href="../../../v/a/s/Vasodilator.html" title="Vasodilator">Vasodilators</a></td>
</tr>
<tr>
<th style=""><a href="../../../g/a/s/Gastrointestinal_tract.html" title="Gastrointestinal tract">Gastrointestinal tract</a></th>
<td><a href="../../../a/n/t/Antacid.html" title="Antacid">Antacids</a>, <a href="../../../a/n/t/Antidiarrhoeal.html" title="Antidiarrhoeal">Antidiarrhoeals</a>, <a href="../../../h/2/-/H2-receptor_antagonist.html" title="H2-receptor antagonist">H2-receptor antagonists</a>, <a href="../../../p/r/o/Proton_pump_inhibitor.html" title="Proton pump inhibitor">Proton pump inhibitors</a>, <a href="../../../l/a/x/Laxative.html" title="Laxative">Laxatives</a></td>
</tr>
<tr>
<th style=""><a href="../../../m/u/s/Muscle.html" title="Muscle">Muscles</a>, <a href="../../../b/o/n/Bone.html" title="Bone">Bones</a>, and <a href="../../../j/o/i/Joint.html" title="Joint">Joints</a></th>
<td><a href="../../../a/n/t/Anti-inflammatory.html" title="Anti-inflammatory">Anti-inflammatories</a>, <a href="../../../d/i/s/Disease-modifying_antirheumatic_drug.html" title="Disease-modifying antirheumatic drug">Antirheumatics</a>, <a href="../../../c/o/r/Corticosteroid.html" title="Corticosteroid">Corticosteroids</a>, <a href="../../../m/u/s/Muscle_relaxant.html" title="Muscle relaxant">Muscle relaxants</a></td>
</tr>
<tr>
<th style=""><a href="../../../a/l/l/Allergy.html" title="Allergy">Allergy</a></th>
<td><a href="../../../a/n/t/Antihistamine.html" title="Antihistamine">Antihistamines</a></td>
</tr>
<tr>
<th style=""><a href="../../../i/n/f/Infection.html" title="Infection">Infections</a> and <a href="../../../i/n/f/Infestation.html" title="Infestation">Infestations</a></th>
<td><a href="../../../a/n/t/Antibiotic.html" title="Antibiotic">Antibiotics</a>, <a href="../../../a/n/t/Antiviral_drug.html" title="Antiviral drug">Antivirals</a>, <a href="../../../v/a/c/Vaccine.html" title="Vaccine">Vaccines</a>, <a href="../../../a/n/t/Antiprotozoal_agent.html" title="Antiprotozoal agent">Antiprotozoals</a>, <a href="../../../a/n/t/Antifungal_drug.html" title="Antifungal drug">Antifungals</a>, <a href="../../../a/n/t/Anthelmintic.html" title="Anthelmintic">Anthelmintics</a></td>
</tr>
<tr>
<th style=""><a href="../../../e/n/d/Endocrine_system.html" title="Endocrine system">Endocrine system</a></th>
<td><a href="../../../c/o/r/Corticosteroid.html" title="Corticosteroid">Corticosteroids</a>, <a href="../../../a/n/t/Anti-diabetic_drug.html" title="Anti-diabetic drug">Anti-diabetics</a></td>
</tr>
<tr>
<th style=""><a href="../../../m/a/l/Malignant.html" title="Malignant">Malignant</a> and <a href="../../../i/m/m/Immune_system.html" title="Immune system">Immune</a> disease</th>
<td><a href="../../../c/h/e/Chemotherapy.html" title="Chemotherapy">Anticancer agents</a>, <a href="../../../i/m/m/Immunosuppressive_drug.html" title="Immunosuppressive drug">Immunosuppressants</a></td>
</tr>
<tr>
<th style=""><a href="../../../r/e/p/Reproductive_system.html" title="Reproductive system">Reproductive system</a></th>
<td><a href="../../../h/o/r/Hormonal_contraception.html" title="Hormonal contraception">Hormonal contraception</a>, <a href="../../../f/e/r/Fertility_medication.html" title="Fertility medication">Fertility agents</a>, <a href="../../../s/e/l/Selective_estrogen_receptor_modulator.html" title="Selective estrogen receptor modulator">Selective estrogen receptor modulators</a></td>
</tr>
<tr>
<th style=""><a href="../../../s/k/i/Skin.html" title="Skin">Skin</a></th>
<td><a href="../../../a/n/t/Antipruritic.html" title="Antipruritic">Antipruritics</a></td>
</tr>
</table>

<!-- 
Pre-expand include size: 42964 bytes
Post-expand include size: 24910 bytes
Template argument size: 14124 bytes
Maximum: 2048000 bytes
-->
<div class="printfooter">
Retrieved from "<a href="http://en.wikipedia.org../../../a/n/t/Antiarrhythmic_agent.html">http://en.wikipedia.org../../../a/n/t/Antiarrhythmic_agent.html</a>"</div>
	    <div id="catlinks"><p class='catlinks'><a href="../../../c/a/t/Special%7ECategories_101d.html" title="Special:Categories">Categories</a>: <span dir='ltr'><a href="../../../a/n/t/Category%7EAntiarrhythmic_agents_8bd5.html" title="Category:Antiarrhythmic agents">Antiarrhythmic agents</a></span> | <span dir='ltr'><a href="../../../c/a/r/Category%7ECardiac_electrophysiology_f2fe.html" title="Category:Cardiac electrophysiology">Cardiac electrophysiology</a></span></p></div>	    <!-- end content -->
	    <div class="visualClear"></div>
	  </div>
	</div>
      </div>
      <div id="column-one">
	<div id="p-cactions" class="portlet">
	  <h5>Views</h5>
	  <ul>
	    <li id="ca-nstab-main"
	       class="selected"	       ><a href="../../../a/n/t/Antiarrhythmic_agent.html">Article</a></li><li id="ca-talk"
	       	       ><a href="../../../a/n/t/Talk%7EAntiarrhythmic_agent_300c.html">Discussion</a></li><li id="ca-current"
	       	       ><a href="http://en.wikipedia.org/wiki/Antiarrhythmic_agent">Current revision</a></li>	  </ul>
	</div>
	<div class="portlet" id="p-logo">
	  <a style="background-image: url(../../../images/wiki-en.png);"
	    href="../../../index.html"
	    title="Main Page"></a>
	</div>
	<script type="text/javascript"> if (window.isMSIE55) fixalpha(); </script>
		<div class='portlet' id='p-navigation'>
	  <h5>Navigation</h5>
	  <div class='pBody'>
	    <ul>
	    	      <li id="n-Main-page"><a href="../../../index.html">Main page</a></li>
	     	      <li id="n-Contents"><a href="../../../c/o/n/Wikipedia%7EContents_3181.html">Contents</a></li>
	     	      <li id="n-Featured-content"><a href="../../../f/e/a/Wikipedia%7EFeatured_content_24ba.html">Featured content</a></li>
	     	      <li id="n-currentevents"><a href="../../../c/u/r/Portal%7ECurrent_events_bb60.html">Current events</a></li>
	     	    </ul>
	  </div>
	</div>
		<div class='portlet' id='p-interaction'>
	  <h5>interaction</h5>
	  <div class='pBody'>
	    <ul>
	    	      <li id="n-About-Wikipedia"><a href="../../../a/b/o/Wikipedia%7EAbout_8d82.html">About Wikipedia</a></li>
	     	      <li id="n-portal"><a href="../../../c/o/m/Wikipedia%7ECommunity_Portal_6a3c.html">Community portal</a></li>
	     	      <li id="n-contact"><a href="../../../c/o/n/Wikipedia%7EContact_us_afd6.html">Contact us</a></li>
	     	      <li id="n-sitesupport"><a href="http://wikimediafoundation.org/wiki/Fundraising">Make a donation</a></li>
	     	      <li id="n-help"><a href="../../../c/o/n/Help%7EContents_22de.html">Help</a></li>
	     	    </ul>
	  </div>
	</div>
		<div id="p-search" class="portlet">
	  <h5><label for="searchInput">Search</label></h5>
	  <div id="searchBody" class="pBody">
	    <form action="javascript:goToStatic(3)" id="searchform"><div>
	      <input id="searchInput" name="search" type="text"
	        accesskey="f" value="" />
	      <input type='submit' name="go" class="searchButton" id="searchGoButton"
	        value="Go" />
	    </div></form>
	  </div>
	</div>
	<div id="p-lang" class="portlet">
	  <h5>In other languages</h5>
	  <div class="pBody">
	    <ul>
	      	      <li>
	      <a href="../../../../de/a/n/t/Antiarrhythmikum.html">Deutsch</a>
	      </li>
	      	      <li>
	      <a href="../../../../es/a/g/e/Agente_antiarr%C3%ADtmico.html">Español</a>
	      </li>
	      	      <li>
	      <a href="../../../../fr/a/n/t/Antiarythmique.html">Français</a>
	      </li>
	      	      <li>
	      <a href="../../../../hu/a/n/t/Antiarritmi%C3%A1s_szerek.html">Magyar</a>
	      </li>
	      	      <li>
	      <a href="../../../../pt/a/n/t/Antiarr%C3%ADtmico.html">Português</a>
	      </li>
	      	    </ul>
	  </div>
	</div>
	      </div><!-- end of the left (by default at least) column -->
      <div class="visualClear"></div>
      <div id="footer">
    <div id="f-poweredbyico"><a href="http://www.mediawiki.org/"><img src="../../../skins/common/images/poweredby_mediawiki_88x31.png" alt="Powered by MediaWiki" /></a></div>	<div id="f-copyrightico"><a href="http://wikimediafoundation.org/"><img src="../../../images/wikimedia-button.png" border="0" alt="Wikimedia Foundation"/></a></div>	<ul id="f-list">
	  	  	  <li id="f-credits">This page was last modified 01:27, 13 March 2007 by Anonymous user(s) of Wikipedia. Based on work by Wikipedia user(s) <a href="../../../b/e/n/User%7EBenjaminevans82_7c6f.html" title="User:Benjaminevans82">Benjaminevans82</a>, <a href="../../../a/b/z/User%7EAbzs2k_5aac.html" title="User:Abzs2k">Abzs2k</a>, <a href="../../../a/x/l/User%7EAxl_2118.html" title="User:Axl">Axl</a>, <a href="../../../w/o/u/User%7EWouterstomp_b006.html" title="User:Wouterstomp">Wouterstomp</a>, <a href="../../../f/v/a/User%7EFvasconcellos_4804.html" title="User:Fvasconcellos">Fvasconcellos</a>, <a href="../../../n/i/e/User%7ENiels_Olson_0d00.html" title="User:Niels Olson">Niels Olson</a>, <a href="../../../k/s/h/User%7EKsheka_e2cf.html" title="User:Ksheka">Ksheka</a>, <a href="../../../a/r/c/User%7EArcadian_5c4b.html" title="User:Arcadian">Arcadian</a>, <a href="../../../t/x/o/User%7ETxomin_60b7.html" title="User:Txomin">Txomin</a>, <a href="../../../e/p/o/User%7EEpolk_d8a6.html" title="User:Epolk">Epolk</a>, UCLABruin, <a href="../../../t/r/a/User%7ETravelbird_9a21.html" title="User:Travelbird">Travelbird</a>, Tony Lim, <a href="../../../b/l/u/User%7EBluebot_e595.html" title="User:Bluebot">Bluebot</a>, <a href="../../../u/t/h/User%7EUthbrian_6843.html" title="User:Uthbrian">Uthbrian</a>, <a href="../../../j/h/e/User%7EJHeuser_7e02.html" title="User:JHeuser">JHeuser</a>, <a href="../../../g/r/i/User%7EGrinBot_48c7.html" title="User:GrinBot">GrinBot</a>, <a href="../../../l/e/o/User%7ELeonardoRob0t_c34e.html" title="User:LeonardoRob0t">LeonardoRob0t</a>, <a href="../../../s/a/l/User%7ESalvadorjo_220f.html" title="User:Salvadorjo">Salvadorjo</a>, <a href="../../../m/a/r/User%7EMartpol_6226.html" title="User:Martpol">Martpol</a>, <a href="../../../a/l/e/User%7EAlex.tan_6c56.html" title="User:Alex.tan">Alex.tan</a>, <a href="../../../e/r/a/User%7EEras-mus_f9f9.html" title="User:Eras-mus">Eras-mus</a>, <a href="../../../e/e/q/User%7EEequor_b13d.html" title="User:Eequor">Eequor</a>, <a href="../../../r/d/s/User%7ERdsmith4_389f.html" title="User:Rdsmith4">Rdsmith4</a>, <a href="../../../t/a/r/User%7ETarek_3966.html" title="User:Tarek">Tarek</a>, <a href="../../../a/a/a/User%7EAAAAA_5820.html" title="User:AAAAA">AAAAA</a>, <a href="../../../n/i/t/User%7ENiteowlneils_bf4c.html" title="User:Niteowlneils">Niteowlneils</a>, <a href="../../../d/i/b/User%7EDiberri_3d04.html" title="User:Diberri">Diberri</a>, <a href="../../../j/f/d/User%7EJfdwolff_9ea6.html" title="User:Jfdwolff">Jfdwolff</a> and <a href="../../../h/u/g/User%7EHugh2414_a633.html" title="User:Hugh2414">Hugh2414</a>.</li>	  <li id="f-copyright">All text is available under the terms of the <a class='internal' href="../../../t/e/x/Wikipedia%7EText_of_the_GNU_Free_Documentation_License_702a.html" title="Wikipedia:Text of the GNU Free Documentation License">GNU Free Documentation License</a>. (See <b><a class='internal' href="../../../c/o/p/Wikipedia%7ECopyrights_92c4.html" title="Wikipedia:Copyrights">Copyrights</a></b> for details.) <br /> Wikipedia&reg; is a registered trademark of the <a href="http://www.wikimediafoundation.org">Wikimedia Foundation, Inc</a>., a US-registered <a class='internal' href="../../../5/0/1/501%28c%29.html#501.28c.29.283.29" title="501(c)(3)">501(c)(3)</a> <a href="http://wikimediafoundation.org/wiki/Deductibility_of_donations">tax-deductible</a> <a class='internal' href="../../../n/o/n/Non-profit_organization.html" title="Non-profit organization">nonprofit</a> <a href="../../../c/h/a/Charitable_organization.html" title="Charitable organization">charity</a>.<br /></li>	  <li id="f-about"><a href="../../../a/b/o/Wikipedia%7EAbout_8d82.html" title="Wikipedia:About">About Wikipedia</a></li>	  <li id="f-disclaimer"><a href="../../../g/e/n/Wikipedia%7EGeneral_disclaimer_3e44.html" title="Wikipedia:General disclaimer">Disclaimers</a></li>	  	</ul>
      </div>
    </div>
  </body>
</html>
